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Introduction
The Fontan procedure using a total cavopulmonary 
connection is the most common procedure performed to 
treat complex congenital cardiac defects not amendable to 
biventricular repair (1-3). Despite the palliative nature of 
the Fontan procedure, good long-term results have been 
reported in patients with ideal hemodynamics conditions, 
with a 20-year survival around 74% (4). However, 
substantial morbidity and mortality have been described, 
often related to thromboembolic complications and 
narrowing of the conduits used (5), because the currently 
available materials are prone to chronic inflammation and 
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they are unable to grow. To overcome these limitations, 
several groups are working on various biocompatible 
materials with growth potential, using pediculated 
autologous pericardial roll or tissue-engineered vascular 
graft using autologous cells and biodegradable scaffolds 
(6,7).
In the present paper, we report on the 2-year results of 
a small series of patients who received a new vascular graft 
based on a bioabsorbable restorative polymer matrix. Early 
postoperative results were reported in 2016 (8). 
Methods
A prospective human clinical investigation to assess the 
safety and performance of this vascular graft (Xeltis AG, 
Zurich, Switzerland) was started on a single center, the 
Bakoulev Center for Cardiovascular Surgery in Moscow, 
Russian Federation. The study was conducted in accordance 
with the Declaration of Helsinki (as revised in 2013). The 
study was approved by the institutional ethics/committee 
(Clinicaltrials.gov number, NCT02377674), and informed 
consent was taken from all the patients.
 Safety of the device was evaluated by monitoring all 
graft-related post-operative complications that required 
redo-surgery, any catheter intervention or which lead to 
death. Clinical and hemodynamic performance of this 
conduit was evaluated by analyzing the incidence of loss of 
functionality requiring intervention.
Five patients (3 males and 2 females) had all underwent 
a previous bidirectional Glenn shunt, 3 had coiling of 
aortopulmonary collaterals, and 1 received a modified 
Blalock Taussig shunt. Average age of the patients at 
implantation was 6.2±2.9 years (range, 4–12 years), with an 
average body mass index of 14.5±2.1 kg/m2. 
Initial diagnosis was tricuspid valve atresia in 3 and 
hypoplastic left heart syndrome in 2 patients. All patients 
underwent preoperative cardiac catheterization with 
hemodynamic evaluation (e.g., direct pulmonary pressure 
assessment).  
Graft implantation between the inferior vena cava and 
the right pulmonary artery as an extracardiac conduit was 
technically successful in all patients as second step of the 
modified Fontan procedure (3 patients received 18 mm 
diameter conduit and 2 patients a 20 mm conduit). Mean 
cardiopulmonary bypass time was 104 min (range, 83– 
120 min). All patients were operated without aortic cross-
clamping. No fenestration was performed in any case.
The data were monitored by an independent clinical 
research company and all potential serious adverse events 
were reviewed by an independent clinical review committee. 
A strict follow-up protocol is performed in all patients. 
At 24 months, control included clinical assessment, blood 
test, ECG, echocardiography, MRI, notification of the 
adverse events (related or not to the implant) and current 
medication. 
Results
The restorative polymer-based vascular conduit is designed 
to be immediately functional like other available devices, 
but its physiochemical characteristics should enable cell 
infiltration and subsequent endogenous tissue formation. 
The conduit is composed of a bioabsorbable supramolecular 
polyester and processed by electrospinning. It is obtained 
by chain-extending poly-caprolactone with 2-ureido-4[1H]-
pyrimidinone (8). 
All patients underwent a complete clinical and imaging 
assessment after 24 months postoperatively. They were all 
doing well with no device-related serious adverse events 
reported in any of them (no obstruction at the level of 
the anastomoses or within the conduit). At 2-year follow-
up, these pleural events had completely resolved. No new 
serious adverse advents were reported during the second 
year of follow-up.
Transthoracic echocardiography (TTE) demonstrated 
anatomical stability and adequate function of the 
extracardiac conduit in all patients. This exam had some 
limitations for the assessment of the proximal and distal 
portions of the conduit, as it was not always possible to 
estimate the proximal and distal diameter and wall thickness 
of the conduits, nor their exact length. However, diameter 
and wall thickness could be visualized approximatively at the 
middle of the conduit: the flow through the conduit showed 
no turbulence or presence of thrombus at 24 months in 4 
patients (Table 1). In one patient some degree of turbulence 
was observed in the conduit, but there was no significant 
reduction of the diameter. No patient presented with more 
than mild systemic atrio-ventricular valve regurgitation. 
No obstruction was detected in the left ventricular 
outflow tract or at the isthmus and/or aortic arch level 
in any of the patients up to 24 months. There was no 
significant change of the ejection fraction at 24 months 
(mean left ventricular ejection fraction was 57.6±6.1 at 
12 months and 59.4%±8.3% at 24 months). Only one 
patient had a decreased left ventricular ejection fraction 
from the early postoperative period (baseline left ventricular 
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ejection fraction was 60% before surgery, fell to 45% at 
1-month follow-up, and was stable at 45% at the 2 years 
visit). This patient underwent coiling of an aorto-pulmonary 
collateral. The medical treatment was changed from digoxin 
to trimetazidine. 
MRI was performed in 4 of 5 patients at the 1-year 
follow-up and in all patients at 2-year follow-up (Table 
2, Figure 1). MRI allowed to routinely assess the conduit 
diameter (proximal, mid and distal conduit) and visualize 
blood flow using 4D flow imaging. There was a little 
change on the MRI concerning conduit diameter from 1- 
to 2-year follow up with an average increasing in diameter 
of 1%, 7% and 5% respectively at superior vena cava (SVC) 
level, mid-segment of the graft, and IVC level (Tables 2,3). 
In one patient, TTE showed somewhat a turbulent flow 
(max. velocity 1.6 m/s), but this was not confirmed by MRI 
4D flow assessment. 
During the first year, 3 patients received warfarin 
and 2 received salicylic acid. At 24-month follow-up, 
anticoagulation regimen was maintained in 4/5 patients and 
one patient under warfarin was switched to salicylic acid. 
Discussion
The Xeltis conduit has been developed and designed to 
induce autologous repair by endogenous tissue restoration 
(patients’ own cells). This could potentially allow 
spontaneous growth of the implant but remains to be 
demonstrated.
The mid-term clinical and hemodynamic results of the 
conduit after 24 months follow-up are very satisfying. There 
are no adverse advents in any of the 5 patients and all of them 
are in very satisfying clinical condition. Echocardiographic 
data did not show any significant changes compared to the 
12-month visit, excepted in one patient in whom some degree 
of turbulent flow was observed, although this finding was not 
confirmed in the MRI study.
No graft-related adverse events have been observed 
to date in any of these five patients. Pleural effusion was 
the most common immediate postoperative side-effect 
following cavopulmonary connection: this has been 
extensively described in patients following the Fontan 
procedure (9,10).
The described conduit has been constructed with a 
restorative polymeric material that allows cells to infiltrate 
the scaffold and so create a vessel with the patient’s own 
tissue. Animal studies have shown that this process starts 
as soon as the conduit has been implanted and continues 
until total endogenous tissue restoration, with functionality 
Table 1 Transthoracic echo and angiography values prior to surgery 
Demographics Value (N=5)
Tricuspid valve atresia 3
Hypoplastic left heart syndrome 2
Previous surgery Glenn shunt (n=5);  
Norwood + modified aorto-
pulmonary (AP) shunt (n=2)
Left ventricular ejection fraction (LVEF) 62.6±3.3
Systolic pulmonary artery pressure 14.8±2.6
Diastolic pulmonary artery pressure 7±0.9
Regurgitation AV valve Minimum to mild
Regurgitation outflow valve None
Outflow tract obstruction isthmus None
Outflow tract obstruction aortic arch None
Table 2 Transthoracic echocardiographic data at 12 and 24 months
Patient No.
12 month 24 month
Mid conduit diameter/
wall thickness
Turbulence Thrombus
Mid conduit diameter/
wall thickness
Turbulence Thrombus
Patient 1 (18 mm) 18/0.4 No No 16/0.6 No No
Patient 2 (20 mm) 20/0.5 No No 17/0.3–0.4 No No
Patient 3 (18 mm) 18/0.5 No No 18/0.55 No No
Patient 4 (18 mm) 17/0.6 No No 18/0.55 Yes No
Patient 5 (20 mm) 18/0.5 No No ND/ND No No
ND, impossible to determine by transthoracic echocardiography.
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taken over completely by the newly formed tissue (11,12). 
At 53 weeks, there were just islands of conduit material left 
within the new vessel. The Xeltis conduit was compared 
to the available Hancock bioprosthetic valved conduit in 
adult sheep in the pulmonary artery position. Animals were 
sacrificed at 2-month (n=6), 6-month (n=6) and 12-month 
(n=6) and the conduits were examined histologically. 
Fifteen animals survived until sacrifice, The Xeltis 
conduits showed mild neo-intimal thickening and begin of 
biodegradation as early as 2-month with an ongoing process 
until 12-month. Only 1 of the 18 animals with a Xeltis 
conduit had significant calcification at 6-months. 
Pathologic specimen did not show any significant 
narrowing of the conduit while neo-intimal thickness 
showed a peak at 6-month. Inflammatory process reached 
a maximum at 6-month, the degradation process at 
12-month. The wall of the Hankock conduits showed 
more neo-intimal thickening, narrowing and calcification 
compared to Xeltis but the leaflets demonstrated minimal 
changes (11,12).
This innovative therapy has the potential to change 
the prognosis for patients treated with extracardiac cavo-
Table 3 Conduit diameter in mm: at surgical implantation (device diameter); at 12 months, and at 24 months (MRI assessment)
Patient No.
Conduit diameter at  
implantation
Conduit diameter at 12 months Conduit diameter at 24 months
SVC Mid IVC SVC Mid IVC
Patient 1 18 16 20 13.2 14* 19.7 14.5
Patient 2 20 16.5 16 19.6 17.4 18.0 19.1 
Patient 3 18 18 18 18 19.4 19.5 19.7
Patient 4 18 17.9 18.2 19.7 18.5 19.7 18.6
Patient 5 20 NA NA NA 18.3 18.0 17.4
*, this patient developed significant narrowing at the level of the superior vena cava (SVC); the reason was not clear but this problem may 
have been induced by insufficient mobilization of the SVC and therefore tension on the anastomosis. MRI evaluation of the conduit was 
assessed at three levels: SVC, in the middle segment of the graft (mid) and at the level of the inferior vena cava (IVC). NA, not available.
Figure 1 One and 2-year MRI controls on frontal views with 4D flow evaluation showing good flow in the vascular graft with no turbulence. 
RPA, right pulmonary artery; SVC, superior vena cava; LPA, left pulmonary artery; IVC, inferior vena cava.
2015. MRI Frontal 2016. MRI Frontal
2015. MRI 4D Flow 2016. MRI 4D Flow
RPA
IVC IVC
LPA
SVC
Conduit Conduit
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pulmonary conduits in the Fontan circulation and in 
pulmonary position (valved conduits) since the currenly 
used materials do not enlarge as the patients grow. This 
means that the diameter of the implanted conduit needs 
to be large enough to allow adult inferior vena cava blood 
flow (13). Again, this may be a reason leading to pulmonary 
vein stenosis when the prosthetic conduit lies in front of the 
right pulmonary veins.
The functionality of the conduit was confirmed by 
TTE and MRI assessment in all patients, showing lack 
of thrombus and significant turbulences with good 
visualization of the blood flow through the conduit. 
However, the TTE had limitations for assessment of the 
proximal and distal portions of the conduit, hardly viewable, 
and the difficulty to estimate the length of the conduit. 
An increasing number of “Fontan patients” are now 
entering adulthood, among growing up congenital 
heart patients and these patients are facing an uncertain 
future (14). Due to the increased survival of these patients, 
long-term complications are becoming more common 
(15,16); they are often related to thromboembolism and 
development of stenosis of the available xenografts or 
artificial conduits (5). Bhat and Sahn have shown that the 
most common reason for reoperation is stenosis of the 
conduit, with an occurrence up to 85% (17). The most 
frequently used conduits for extracardiac Fontan procedure 
include non-absorbable synthetic vascular grafts such as the 
ring-reinforced Gore-Tex (PTFE) and Dacron.
Regarding the anticoagulation: the standard protocol 
includes oral anticoagulation during the first year following 
total cavo-pulmonary connection in patients without 
contra-indications. In those with any contra-indication (e.g., 
hemorrhagic diathesis), salicylic acid was administered with 
a dosage of 100 mg per day.  
The novel restorative vascular graft may provide an 
interesting alternative for these patients, since it may 
help reducing the need for reoperation related to the 
complications associated to a permanent implant. Moreover, 
the development of an endothelialized thrombo-resistant 
intimal surface that integrates naturally in the environment 
could decrease the need for anticoagulation therapy, 
requiring none to minimal anticoagulation. This would 
minimize anticoagulation-related complications. This small 
series confirms the safety of the polymer conduit up to 
24 months and more and makes this material non-inferior 
to currently available conduits (18-20). These benefits 
may potentially lead to a significant improved quality of 
life for congenital heart patients requiring surgery with 
graft implantation not only in the central venous pressure 
segment but also in other locations.
Conclusion and limitations
This small series has a limited follow-up interval but shows 
that the restorative device can be successfully implanted 
and may be free from material-related complications. Up to 
24 months there was also no documented loss of function. 
One of the most commonly reported complications after a 
Fontan procedure, namely graft stenosis and compression 
of the pulmonary veins was not observed at 24 months 
follow-up in any of the patients. We are confident that 
the potential for ongoing narrowing will decrease once 
the polymer has been absorbed. The observational study 
will continue to examine the evolution of the conduit in 
these 5 patients for up to 5 years to gain more information 
concerning the safety and performance of the device. 
Acknowledgments
Funding: None.
Footnote
Data Sharing Statement: Available at http://dx.doi.
org/10.21037/jtd-19-739
Conflicts of Interest: All authors have completed the ICMJE 
uniform disclosure form (available at http://dx.doi.
org/10.21037/jtd-19-739). This clinical study was sponsored 
by Xeltis, and all payments were made to the hospital. The 
authors attest that they had full freedom to explore the data 
and analyze the results independently from the sponsor 
and that they had sole authority to make the final decision 
to submit the material for publication. AL, MC and OS 
are employed by and hold stock options of Xeltis. ATC is a 
member of the Medical Advisory Board of Xeltis. The other 
authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects 
of the work in ensuring that questions related to the accuracy 
or integrity of any part of the work are appropriately 
investigated and resolved. The study was conducted in 
accordance with the Declaration of Helsinki (as revised in 
2013). The study was approved by the institutional ethics/
committee (Clinicaltrials.gov number, NCT02377674). and 
informed consent was taken from all the patients.
4173Journal of Thoracic Disease, Vol 12, No 8 August 2020
© Journal of Thoracic Disease. All rights reserved.   J Thorac Dis 2020;12(8):4168-4173 | http://dx.doi.org/10.21037/jtd-19-739
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and the 
original work is properly cited (including links to both the 
formal publication through the relevant DOI and the license). 
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
1. Badhwar V, Rankin JS, Thourani VH, et al. The Society 
of Thoracic Surgeons Adult Cardiac Surgery Database: 
2018 Update on Research: Outcomes Analysis, Quality 
Improvement and Patient Safety. Ann Thorac Surg 
2018;106:8-13.
2. Norwood WI Jr, Jacobs ML, Murphy JD. Fontan 
procedure for hypoplastic left heart syndrome. Ann 
Thorac Surg 1992;54:1025-9.
3. de Leval MR, Kilner P, Gewillig M, et al. Total 
cavopulmonary connection: a logical alternative to 
atriopulmonary connection for complex Fontan operations. 
Experimental studies and early clinical experience. J 
Thorac Cardiovasc Surg 1988;96:682-95.
4. Downing TE, Allen KY, Glatz AC, et al. Long-term 
survival after the Fontan operation: Twenty years of 
experience at a single center. J Thorac Cardiovasc Surg 
2017;154:243-53.e2.
5. Fredenburg TB, Johnson TR, Cohen MD. The Fontan 
Procedure: Anatomy, Complications, and Manifestations 
of Failure. Radiographics 2011:31:453-63.
6. Adachi I, Yagihara T, Kagisaki K, et al. Fontan operation 
with a viable and growing conduit using pedicled 
autologous pericardial roll: serial changes in conduit 
geometry. J Thorac Cardiovasc Surg 2005;130:1517-22.
7. Shinoka T. Development of a tissue-engineering vascular 
graft for use in congenital heart surgery. EBioMedicine 
2014;1:12-3.
8. Bockeria LA, Svanidze O, Kim A, et al. Total cavo-
pulmonary connection with a new bioabsorbable vascular 
graft: First clinical experience. J Thorac Cardiovasc Surg 
2017;153:1542-50.
9. Mascio CE, Austin EH. Pleural effusions following the 
Fontan procedure. Curr Opin Pulm Med 2010;16:362-6.
10. Gupta A, Daggett C, Behera S, et al. Risk factors for 
persistent pleural effusions after the extracardiac Fontan 
procedure. J Thorac Cardiovasc Surg 2004;127:1664-9.
11. Schoen FJ, Cox MAJ, Warnack B, et al. Vascular 
remodelling of a novel absorbable polymeric conduit in 
the ovine pulmonary circulation. Poster presented at the 
World Biomaterials Conference, Montreal, Canada, May 
17-22, 2016.
12. Bennink G, Torii S, Brugmans M, et al. A novel restorative 
pulmonary valved conduit in a chronic sheep model: Mid-
term hemodynamic function and histologic assessment. J 
Thorac Cardiovasc Surg 2018;155:2591-601.e3.
13. Alexi-Meskishvili V, Ovroutski S, Ewert P, et al. Optimal 
conduit size for extracardiac Fontan operation. Eur J 
Cardiothorac Surg 2000;18:690-5.
14. Gersony W.M. Fontan operation after 3 decades: what we 
have learned. Circulation 2008;117:13-5.
15. Navarro-Aguilar V, Flors L, Calvillo P, et al. Fontan 
procedure: imaging of normal post-surgical anatomy and 
the spectrum of cardiac and extracardiac complications. 
Clin Radiol 2015;70:295-303.
16. Khairy P, Fernandes SM, Mayer JE, et al. Long-term 
survival, modes of death, and predictors of mortality in 
patients with Fontan surgery. Circulation 2008;117:85-92.
17. Bhat AH, Sahn DJ. Congenital heart disease never goes 
away, even when it has been 'treated': the adult with 
congenital heart disease. Curr Opin Pediatr 2004;16:500-7.
18. Dabal RJ, Kirklin JK, Kukreja M, et al. The modern 
Fontan operation shows no increase in mortality out 
to 20 years: a new paradigm. J Thorac Cardiovasc Surg 
2014;148:2517-23.e1.
19. Lee C, Lee CH, Hwang SW, et al. Midterm follow-up of the 
status of Gore-Tex graft after extracardiac conduit Fontan 
procedure. Eur J Cardiothorac Surg 2007;31:1008-12.
20. van Brakel TJ, Schoof PH, de Roo F, et al. High Incidence 
of Dacron Conduit Stenosis for Extracardiac Fontan 
Procedure. J Thorac Cardiovasc Surg 2014;147:1568-72.
Cite this article as: Bockeria L, Carrel T, Lemaire A, 
Makarenko V, Kim A, Shatalov K, Cox M, Svanidze O. Total 
cavopulmonary connection with a new restorative vascular 
graft: results at 2 years. J Thorac Dis 2020;12(8):4168-4173. 
doi: 10.21037/jtd-19-739
